A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is to assess the pharmacokinetic interaction between ASP1941 and Miglitol in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: 1-Deoxynojirimycin; Ipragliflozin; Miglitol

Criteria

Inclusion Criteria:

• Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and laboratory tests

• Body weight ; ≥50.0 kg, <80.0 kg

• Body Mass Index ; ≥17.6, <26.4

• Written informed consent has been obtained

Exclusion Criteria:

• Received any investigational drugs within 120 days before the screening assessment

• Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment

• Received medication within 7 days before hospital admission

• A deviation from the assessment criteria of physical examinations or laboratory tests at screening or upon admission

• History of drug allergies

• With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases

• Previous treatment with ASP1941